Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Treatment for Older Prostate Cancer Patients

Disparities in a Southern State

Datos Bibliográficos

ID9102930
AutoresMaria Pisu (University of Alabama at Birmingham, autor de correspondencia), Joann S Oliver (0000-0002-5623-6480, University of Alabama), Young-Il Kim (0000-0001-6806-4551), Young‐Il Kim (0000-0002-0145-7382, University of Alabama at Birmingham, autor de correspondencia), Keith Elder (0000-0002-4932-0852, University of Alabama at Birmingham), Michelle Martin, Michelle D Martin (0009-0003-8001-6714, University of Alabama at Birmingham, autor de correspondencia), Lisa C Richardson (0000-0002-9555-7674)
Año2010
Volumen48
Número10
Páginas915-922
Fecha de publicación2010-10-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0b013e3181eb31a8
PMID20733530
OpenAlexW2027670722
IdiomaEN
Referencias citadas29

BACKGROUND: Black prostate cancer patients are less likely to receive aggressive therapy (AT) than Whites: reported rates for patients ≥ 65 years old are about 55% versus 65%. Little is known about treatment rates in socioeconomically deprived states with large Black populations like Alabama. STUDY DESIGN: Medicare claims and Alabama Statewide Cancer Registry records were linked for Alabamian men in Medicare fee-for-service diagnosed with loco-regional prostate cancer in 2000-2002. The association between race and likelihood of: (1) AT (prostatectomy or external beam radiation therapy [EBRT] or brachytherapy); (2) hormone therapy (primary androgen deprivation therapy [ADT] or orchiectomy); (3) <30 days of EBRT; and (4) <6 months of ADT, was investigated adjusting for age, clinical tumor stage, grade, Comorbidity Index, and census tract proportion of Black residents, of persons living below poverty and with ≤ high school. RESULTS: Of 3561 patients, 71.2% received AT and 38.3% hormone therapy. Blacks were less likely to receive AT (64.3% vs. 73.0%, adjusted [adj.] OR: 0.80, CI: 0.67-0.96). There was no difference between Blacks and Whites in the likelihood of receiving hormone therapy (40.8% vs. 37.7%, adj. OR: 1.10, CI: 0.91-1.34), <30 days of EBRT (30.5% vs. 31.5%, adj. OR: 0.98, CI: 0.72-1.32) or <6 months of ADT (50.7% vs. 54.0%, adj. OR: 0.84, CI: 0.63-1.12). CONCLUSIONS: In Alabama, there were racial differences in utilization of aggressive treatment for locoregional prostate cancer. Research should investigate factors associated with prostate cancer treatment among older men, such as patient behavior and access to care

Androgen deprivation therapy · Brachytherapy · Breast cancer · Cancer · Cancer registry · Comorbidity · Gynecology · Hormone therapy · Prostate cancer · Prostatectomy · Radiation therapy · Cancer survivorship and care · Internal Medicine · Medicine · Oncology · Prostate Cancer Diagnosis and Treatment · Prostate Cancer Treatment and Research

  • Development of a comorbidity index using physician claims data

    Open Access•Carrie N Klabunde, Arnold L Potosky et al.•Journal of Clinical Epidemiology•2000

  • Racial and Ethnic Disparities in the Receipt of Cancer Treatment

    Vickie L Shavers•CancerSpectrum Knowledge…•2002

  • Who You Are and Where You Live

    Amitabh Chandra•Medical Care•2009

  • Predictors of Aggressive Therapy for Nonmetastatic Prostate Carcinoma in Massachusetts From 1998 to 2002

    Amanda J Rose, Adam J Rose et al.•Medical Care•2007

  • The Influence of Patient Race and Social Vulnerability on Urologist Treatment Recommendations in Localized Prostate Carcinoma

    Thomas D Denberg, Fernando J Kim et al.•Medical Care•2006

Velocidad de citaciónhistorical
Altamente citadoNo
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae